Shionogi & Co., Ltd.
Shionogi & Co., Ltd.
- Market cap
- $22.07B
- P/E ratio
- 11.01
Your view on SGIOF
Overview
What the company does, where it operates, and who runs it.
About Shionogi & Co., Ltd.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Isao Teshirogi
- Headquarters
- 1-8, Doshomachi 3-chome, Osaka, JP
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Isao Teshirogi
- Headquarters
- 1-8, Doshomachi 3-chome, Osaka, JP
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment.
It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity.
In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19.
Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs.
The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Shionogi & Co., Ltd. from FRC's valuation model, read against the market price. SGIOF last traded at $25.94, 11.0× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Shionogi & Co., Ltd.. Starting points for Shionogi & Co., Ltd.: P/E 11.0, EPS $283.22, beta -0.02 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Shionogi & Co., Ltd.. Shionogi & Co., Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Shionogi & Co., Ltd.. Trailing twelve-month EPS for Shionogi & Co., Ltd. stands at $283.22. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterDec 2026 | This yearYear to Mar 2027 | Next yearYear to Mar 2028 |
|---|---|---|---|---|
| Average estimate | JPY 64.31 | JPY 64.77 | JPY 267.75 | JPY 269.13 |
| Lowest estimate | JPY 60.56 | JPY 64.52 | JPY 251.97 | JPY 253.27 |
| Highest estimate | JPY 68.14 | JPY 65.02 | JPY 287.69 | JPY 289.17 |
| Number of analysts | 1 | 1 | 2 | 3 |
| A year ago | JPY 0.351 | JPY 0.711 | JPY 242.871 | — |
| Growth vs a year ago | — | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterDec 2026 | This yearYear to Mar 2027 | Next yearYear to Mar 2028 |
|---|---|---|---|---|
| Average estimate | JPY 186.65B | JPY 186.45B | JPY 712.79B | JPY 761.04B |
| Lowest estimate | JPY 178.10B | JPY 176.76B | JPY 693.62B | JPY 713.32B |
| Highest estimate | JPY 194.97B | JPY 196.65B | JPY 739.43B | JPY 818.92B |
| Number of analysts | 5 | 5 | 10 | 11 |
| A year ago | JPY 139.87B | JPY 162.13B | JPY 502.82B | — |
| Growth vs a year ago | +33.4% | +15.0% | +41.8% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Shionogi & Co., Ltd.. Shionogi & Co., Ltd. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| RDDTFRadient Technologies Inc. | Healthcare | OTC | $5,399 | ||
| RDHLRedHill Biopharma Ltd. | Healthcare | NASDAQ | $883,143 | ||
| RDYDr. Reddy's Laboratories Limited | Healthcare | NYSE | $12.4B | ||
| REZNFStreet Capital Inc. | Healthcare | OTC | $1.4M | ||
| RGCRegencell Bioscience Holdings Limited | Healthcare | NASDAQ | $2.1B | ||
| RGT.AXArgent BioPharma Limited | Healthcare | ASX | — | ||
| RLBDReal Brands, Inc. | Healthcare | OTC | $269,064 | ||
| RMTIRockwell Medical, Inc. | Healthcare | NASDAQ | $23.5M | ||
| ROMJ.VRubicon Organics Inc. | Healthcare | TSXV | $22.0M | ||
| ROMJFRubicon Organics Inc. | Healthcare | OTC | $24.1M | ||
| RVV.CNRevive Therapeutics Ltd. | Healthcare | CNQ | $6.5M | ||
| RVVQFRavenQuest BioMed Inc. | Healthcare | OTC | $1,236 | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Shionogi & Co., Ltd.. Coverage tracks Shionogi & Co., Ltd. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Shionogi & Co., Ltd.